Under Armour (NYSE:UA) (NYSE:UAA) has often been called the “next Nike (NYSE:NKE).” For the better part of a decade, that moniker rang true — it posted double-digit sales growth every year since its IPO in 2005 and quickly became a Wall Street darling.
But over the past three years, shares of Under Armour have lost more than half their value, while shares of Nike rallied nearly 50% — making the “next Nike” a much worse investment than the “original” one. Will that trend continue this year? Let’s take a look at both companies’ businesses, their growth trajectories, and valuations to find out.
Image source: Under Armour.
How are Nike and Under Armour different?
Sixty-three percent of Nike’s revenue came from footwear last quarter, 27% camefrom apparel, and the rest came from athletic equipment. The company is well diversified across the world, with only 45% of its top line coming from the North American market during the quarter.
Best Value Stocks To Invest In 2018: Flagstar Bancorp, Inc.(FBC)
Advisors’ Opinion:
- [By Dustin Blitchok]
When Alessandro DiNello was named CEO of Flagstar Bancorp Inc (NYSE: FBC) in 2013, the bank was on a financial precipice.
The bank’s business was almost entirely mortgages. As the industry unraveled nationally, Flagstar accepted $267 million in TARP money in 2009 — as well as private equity financing — to maintain solvency.
Best Value Stocks To Invest In 2018: Cytokinetics, Incorporated(CYTK)
Advisors’ Opinion:
- [By Lisa Levin]
Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 27 percent to $8.12 on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international Phase 3 study showed tiraemtive did not meet the primary endpoint of change from baseline in slow vital capacity, or SVS, evaluated at 24 weeks, as well the secondary endpoints evaluated at 48 weeks.
- [By Paul Ausick]
Cytokinetics Inc. (NASDAQ: CYTK) dropped about 37% Tuesday to post a new 52-week low of $7.00 after closing at $11.10 on Monday. The 52-week high is $17.20. Volume was around 7 million, about 14 times the daily average of less than 500,000. The company’s ALS drug failed ti meet its endpoint in a phase 3 study.
- [By Chris Lange]
Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesdays session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firms Phase 3 clinical trial of tirasemtiv did not meet the primary endpoint or any of the secondary endpoints.
Best Value Stocks To Invest In 2018: Coherus BioSciences, Inc.(CHRS)
Advisors’ Opinion:
- [By Ben Levisohn]
Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:
Agence France-Presse/Getty Images
The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.
- [By Lisa Levin] Gainers
Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Lisa Levin]
Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.
